Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22

Benzinga · 17h ago
Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $20 to $22.